Back to Search
DR. MARY MOSES HITT MD
MD
Hospitalist Physician
NPI: 1073132775Individual
Specialties, Licenses & Credentials
Hospitalist PhysicianPrimary
Hospitalist
Code: 208M00000X
31664(MS)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
1073132775(MS)
Research & Publications (20)
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
PMID 16476986·J Gen Virol·2006
4-observational
A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter.
PMID 16389604·J Gene Med·2006
7-preclinical
Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
PMID 15944305·J Immunol·2005
4-observational
Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.
PMID 16250889·Curr Gene Ther·2005
6-review
Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
PMID 15034014·J Immunol·2004
7-preclinical
Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
PMID 15034071·J Immunol·2004
7-preclinical
Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth.
PMID 15184878·Oncogene·2004
7-preclinical
The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
PMID 15451460·Mol Ther·2004
7-preclinical
Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
PMID 15528375·J Immunol·2004
4-observational
Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.
PMID 15531044·Vaccine·2004
7-preclinical
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
PMID 14502228·Cancer Gene Ther·2003
3-trial
Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors.
PMID 11812278·Hum Gene Ther·2002
7-preclinical
Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model.
PMID 11945067·Mol Ther·2002
7-preclinical
Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.
PMID 11313802·Gene Ther·2001
7-preclinical
Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
PMID 11477456·Cancer Gene Ther·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 971 LAKELAND DR STE 356
JACKSON, MS 39216 - Phone
- (601) 200-4644
Quick Facts
- NPI
- 1073132775
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile